Does antiretroviral therapy cause congenital malformation? A systematic review and Meta-analysis.
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
HowevOBJECTIVES: This meta-analysis investigated the risk of congenital anomalies among infants of human immunodeficiency virus-infected pregnant women who were exposed to antiretroviral therapy (ART). METHODS: Cohort studies, case-control studies, randomized controlled trials, and controlled clinical trials were reviewed by searching MEDLINE/PubMed, Embase, Web of Science, Scopus, AIDSLINE, CINAHL, Cochrane Library, and Google/Google Scholar. Methodological quality was assessed using the GRADE evaluation. A DerSimonian and Laird random-effects model was used. Subgroup analyses and meta-regression were used to investigate heterogeneity. RESULTS: The electronic searches yielded 765 items. After quality assessment and grading, 30 studies were suitable for meta-analysis. In total, 1,461 congenital anomalies were found among 53,186 births. Children born to women receiving combined antiretroviral therapy (cART) had an approximately 10% higher risk of developing congenital anomalies (relative risk [RR], 1.09; 95% confidence interval [CI], 1.04 to 1.14). A subgroup analysis found no significant difference in the risk of congenital anomalies between cART and efavirenz users. However, zidovudine and protease inhibitor (RR, 1.09; 95% CI, 1.00 to 1.19) users were found to have a 10% increased risk of congenital anomalies, and integrase inhibitor users had a 60% increase in risk (RR, 1.61; 95% CI, 1.60 to 2.43). The subgroup results should be interpreted cautiously because of the moderate heterogeneity (I2=58%). CONCLUSIONS: The use of protease inhibitors, integrase inhibitors, zidovudine, and newer drugs should be carefully considered in pregnant women. Further studies are needed to address environmental, nutrition, and adherence factors related to ART. Establishing a congenital anomalies surveillance system is recommended.
Abstract
HowevOBJECTIVES: This meta-analysis investigated the risk of congenital anomalies among infants of human immunodeficiency virus-infected pregnant women who were exposed to antiretroviral therapy (ART). METHODS: Cohort studies, case-control studies, randomized controlled trials, and controlled clinical trials were reviewed by searching MEDLINE/PubMed, Embase, Web of Science, Scopus, AIDSLINE, CINAHL, Cochrane Library, and Google/Google Scholar. Methodological quality was assessed using the GRADE evaluation. A DerSimonian and Laird random-effects model was used. Subgroup analyses and meta-regression were used to investigate heterogeneity. RESULTS: The electronic searches yielded 765 items. After quality assessment and grading, 30 studies were suitable for meta-analysis. In total, 1,461 congenital anomalies were found among 53,186 births. Children born to women receiving combined antiretroviral therapy (cART) had an approximately 10% higher risk of developing congenital anomalies (relative risk [RR], 1.09; 95% confidence interval [CI], 1.04 to 1.14). A subgroup analysis found no significant difference in the risk of congenital anomalies between cART and efavirenz users. However, zidovudine and protease inhibitor (RR, 1.09; 95% CI, 1.00 to 1.19) users were found to have a 10% increased risk of congenital anomalies, and integrase inhibitor users had a 60% increase in risk (RR, 1.61; 95% CI, 1.60 to 2.43). The subgroup results should be interpreted cautiously because of the moderate heterogeneity (I2=58%). CONCLUSIONS: The use of protease inhibitors, integrase inhibitors, zidovudine, and newer drugs should be carefully considered in pregnant women. Further studies are needed to address environmental, nutrition, and adherence factors related to ART. Establishing a congenital anomalies surveillance system is recommended.
참고문헌 (37)
- Sebitloane HM, "The impact of highly active antiretroviral therapy on obstetric conditions : a review", Eur J Obstet Gynecol Reprod Biol, 210, pp.126~131 (2017)
- Nurutdinova D, "A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV", Expert Opin Drug Saf, 8, pp.683~694 (2009)
- Bérard A, "Antiretroviral combination use during pregnancy and the risk of major congenital malformations", AIDS, 31, pp.2267~2277 (2017)
- Gibb DM, "Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial", PLoS Med, 9, pp.e1001217~ (2012)
- Williams PL, "Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants", JAMA Pediatr, 169, pp.48~55 (2015)
- Foster C, "HIV and mitochondrial toxicity in children", J Antimicrob Chemother, 61, pp.8~12 (2008)
- Zash RM, "What is the risk of major congenital abnormalities among women on antiretroviral therapy?", AIDS, 32, pp.403~404 (2018)
- Mofenson LM, "Safety of pediatric HIV elimination : the growing population of HIV-and antiretroviral-exposed but uninfected infants", PLoS Med, 11, pp.e1001636~ (2014)
- Prestes-Carneiro LE, "Antiretroviral therapy, pregnancy, and birth defects: a discussion on the updated data", HIV AIDS(Auckl), 5, pp.181~189 (2013)
- Nso Roca AP, "Pathology in children of HIV women", Indian J Pediatr, 76, pp.1125~1130 (2009)
- Prieto LM, "Birth defects in a cohort of infants born to HIV-infected women in Spain, 2000-2009", BMC Infect Dis, 14, pp.700~ (2014)
- Venhoff N, "Mitochondrial disease in the offspring as a result of antiretroviral therapy", Expert Opin Drug Saf, 5, pp.373~381 (2006)
- Alemu FM, "Antiretroviral therapy and pregnancy outcomes in developing countries : a systematic review", Int J MCH AIDS, 3, pp.31~43 (2015)
- Colbers A, "Pharmacological considerations on the use of antiretrovirals in pregnancy", Curr Opin Infect Dis, 26, pp.575~588 (2013)
- Bulterys M, "Preconception antiretroviral therapy and birth defects: what is needed?", AIDS, 28, pp.2777~2780 (2014)
- Guitart-Mampel M, "Imbalance in mitochondrial dynamics and apoptosis in pregnancies among HIV-infected women on HAART with obstetric complications", J Antimicrob Chemother, 72, pp.2578~2586 (2017)
- Tricco AC, "Safety and effectiveness of antiretroviral therapies for HIV-infected women and their infants and children : protocol for a systematic review and network meta-analysis", Syst Rev, 3, pp.51~ (2014)
- Williams PL, "Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design", AIDS, 30, pp.133~144 (2016)
- "Assessing harms when comparing medical interventions. In: Methods guide for effectiveness and comparative effectiveness reviews; 2008"[URL]
- "Carrying out a literature review; 2002"[URL]
- "Cochrane handbook for systematic reviews of interventions 4.2.6; 2006"[URL]
- International statistical classification of diseases and related health problems, "World Health Organization", World Health Organization, 81~110 (2010)
- Sanderson S, "Tools for assessing quality and susceptibility to bias in observational studies in epidemiology : a systematic review and annotated bibliography", Int J Epidemiol, 36, pp.666~676 (2007)
- Guyatt G, "GRADE guidelines : 1. Introduction-GRADE evidence profiles and summary of findings tables", J Clin Epidemiol, 64, pp.383~394 (2011)
- Shamliyan T, "A systematic review of tools used to assess the quality of observational studies that examine incidence or prevalence and risk factors for diseases", J Clin Epidemiol, 63, pp.1061~1070 (2010)
- Kelley GA, "Statistical models for meta-analysis : a brief tutorial", World J Methodol, 2, pp.27~32 (2012)
- Chaimani A, "A hands-on practical tutorial on performing meta-analysis with Stata", Evid Based Ment Health, 17, pp.111~116 (2014)
- "Cochrane handbook for systematic reviews of interventions version 5.1.0" (2011)[URL]
- Sibiude J, "Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy", AIDS, 35, pp.219~226 (2021)
- Borenstein M, "Introduction to meta-analysis", pp.277~292 (2009), John Wiley & Sons
- Harbord RM, "Meta-regression in Stata", Stata J, 8, pp.493~519 (2008)
- Mofenson LM, "Antiretroviral therapy and adverse pregnancy outcome: the elephant in the room?", J Infect Dis, 213, pp.1051~1054 (2016)
- Powis KM, "Protease inhibitors and adverse birth outcomes: is progesterone the missing piece to the puzzle?", J Infect Dis, 211, pp.4~7 (2015)
- Brogly SB, "Birth defects among children born to human immunodeficiency virus-infected women : pediatric AIDS clinical trials protocols 219 and 219C", Pediatr Infect Dis J, 29, pp.721~727 (2010)
- Velinov M, "Mitochondrial T9098C sequence change in the MTATP6 gene and development of severe mitochondrial disease after in utero antiretroviral prophylaxis", Pharmacotherapy, 29, pp.1491~ (2009)
- Brogly SB, "In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children", AIDS, 21, pp.929~938 (2007)
- Ford N, "Safety of efavirenz in the first trimester of pregnancy : an updated systematic review and meta-analysis", AIDS, 28(Suppl 2), pp.S123~S131 (2014)